[1] Zhang J, Wang Y, Yin Q, et al. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy[J]. Int J Clin Exp Pathol, 2013, 6(7): 1380-1391.
[2] Wang L, Di LJ. BRCA1 and estrogen/estrogen receptors in breast cancer: where they interact?[J]. Int J Biol Sci, 2014, 10(5): 566-575.
[3] Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triplenegative breast cancer[J]. Ann Oncol, 2009, 20(5): 862-867.
[4] Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCApositive and BRCAnegative breast cancer[J]. J Clin Oncol, 2008, 26(26): 4282-4288.
[5] Bayraktar S, GutierrezBarrera AM, Lin H, et al. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations[J]. Clin Exp Metastasis, 2013, 30(5): 631-642.
[6] Byrski T, Gronwald J, Huzarski T, et al. Response to neoadjuvant chemotherapy in women with BRCA1positive breast cancers[J]. Breast Cancer Res Treat, 2008, 108(2): 289-296.
[7] Chen W, Pan K, Ouyang T, et al. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or earlyonset breast cancer[J]. Breast Cancer Res Treat, 2009, 117(1): 55-60.
[8] Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to ′′triplenegative′′ breast cancer in Ashkenazi women[J]. Breast Cancer Res Treat, 2011, 129(1): 185-190.
[9] Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer[J]. J Clin Oncol, 2006, 24(36): 5652-5657.
[10] Kwong A, Wong LP, Wong HN, et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer[J]. HUGO J, 2009, 3(1-4): 63-76.
[11] Lee E, MckeanCowdin R, Ma H, et al. Characteristics of triplenegative breast cancer in patients with a BRCA1 mutation: results from a populationbased study of young women[J]. J Clin Oncol, 2011, 29(33): 4373-4380.
[12] Li WF, Hu Z, Rao NY, et al. The prevalence of BRCA1 and BRCA2 germline mutations in highrisk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified[J]. Breast Cancer Res Treat, 2008, 110(1): 99-109.
[13] Musolino A, Bella MA, Bortesi B, et al. BRCA mutations, molecular markers, and clinical variables in earlyonset breast cancer: a populationbased study[J]. Breast, 2007, 16(3): 280-292.
[14] Noh JM, Han BK, Choi DH, et al. Association between BRCA mutation status, pathological findings, and magnetic resonance imaging features in patients with breast cancer at risk for the mutation[J]. J Breast Cancer, 2013, 16(3): 308-314.
[15] Ou J, Wu T, Sijmons R, et al. Prevalence of BRCA1 and BRCA2 germline mutations in breast cancer women of multiple ethnic region in northwest China[J]. J Breast Cancer, 2013, 16(1): 50-54.
[16] Phuah SY, Looi LM, Hassan N, et al. Triplenegative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with earlyonset and familial breast cancer, but not in women with isolated lateonset breast cancer[J]. Breast Cancer Research, 2012, 14(6): R142-150.
[17] Pristauz G, Petru E, Stacher E, et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations[J]. Histopathology, 2010, 57(6): 877-884.
[18] Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes[J]. Clin Cancer Res, 2009, 15(7): 2302-2310.
[19] Xu J, Wang B, Zhang Y, et al. Clinical implications for BRCA gene mutation in breast cancer[J]. Mol Biol Rep, 2012, 39(3): 3097-3102.
[20] Yip CH, Taib NA, Choo WY, et al. Clinical and pathologic differences between BRCA1, BRCA2, and nonBRCAassociated breast cancers in a multiracial developing country[J]. World J Surg, 2009, 33(10): 2077-2081.
[21] Zhang J, Pei R, Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer[J]. Breast Cancer Res Treat, 2012, 132(2): 421-428.
[22] 刘军杰, 陈圆圆, 李智贤, 等. 广西地区散发性乳腺癌BRCA1突变及其相关临床、组织病理特征的研究[J]. 广西医科大学学报, 2013, 30(4): 496-499.
[23] 李文凤. 中国家族性/早发性乳腺癌人群中BRCA1和BRCA2基因突变的研究[D]. 上海:复旦大学, 2007.
[24] 杨云振. 宁夏地区回、汉族乳腺癌BRCA1基因突变分析[D]. 银川:宁夏医科大学, 2010.
[25] 欧江华, 吴涛, 倪多, 等. 68例中国新疆多民族地区遗传性乳腺癌患者BRCA1和BRCA2突变研究[J]. 中国肿瘤临床, 2012, 29(20): 1539-1541.
[26] 王景, 陈耀平, 康毓芝, 等. 宁夏回族乳腺癌BRCA1基因突变与ER、PR、CerbB2表达的关系[J]. 宁夏医科大学学报, 2011, 33(12): 1135-1137.
[27] 刘静, 张娟, 欧阳涛, 等. 中国汉族BRCA1/2突变的乳腺癌家系中其他肿瘤发病风险分析[J]. 国际肿瘤学杂志, 2013, 40(5): 389-392. |